The FDA has approved inclisiran (Leqvio) for first-line use in lowering LDL cholesterol, even without combining it with ...

The FDA has approved a labeling update for Leqvio (inclisiran) allowing for first-line use in the treatment of hypercholesterolemia.

The updated label no longer requires Leqvio (inclisiran) to be used in combination with statins for low-density lipoprotein ...

The US Food and Drug Administration (FDA) has approved a label update for Swiss pharma giant Novartis’ Leqvio (inclisiran), ...

The US Food and Drug Administration approved the revised label for inclisiran, a small interfering RNA that reduces the ...

Leqvio (inclisiran) is a prescription injection that helps lower levels of low-density lipoprotein cholesterol (LDL), often called “bad” cholesterol, which is a major risk factor for heart ...

Novartis announced today that the US Food and Drug Administration (FDA) has approved a label update for Leqvio® (inclisiran), enabling its use as monotherapy along with diet and exercise to reduce low ...

Researchers introduced the PREVENT risk age equations to help determine risk of cardiovascular disease. (JAMA Cardiology) A ...

(RTTNews) - Novartis announced Thursday said that the US Food and Drug Administration (FDA) has approved a label update for Leqvio (inclisiran), enabling its use as monotherapy along with diet and ...

Leqvio, in combination with maximally tolerated statin therapy, is administered as an initial single subcutaneous injection, a second dose at 3 months, and continued treatment once every 6 months.

For Leqvio’s launch, Novartis is taking a population health-based approach at 200 large U.S. healthcare systems in an effort to identify eligible patients. Among them, at least 50 systems have ...

Leqvio is supplied as a 284mg/1.5mL (189mg/mL) injection in a single-dose prefilled syringe. Treatment is administered by a health care professional.